MYC and acute myeloid leukemia: We observed that the treatment of AML cells either with HDACi or with APTO253 resulted in a dose-dependent decrease of MYC levels and we demonstrated that cells resistant to MYC inhibition in response to araC-mediated DNA damage failed to upregulate MICA.